Polymorphisms in CTLA-4 but not tumor necrosis factor-α or interleukin 1β genes are associated with Wegener's granulomatosis

Journal of Rheumatology

Volumn 27, Issue 2, 2000, Pages 397-401

  Huang, Deren ^a   Giscombe, Ricardo ^a   Zhou, Yihua ^a   Lefvert, Ann Kari ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Costimulator; CTLA 4; Interleukin 1 ; Polymorphism; Tumor Necrosis Factor ; Wegener's Granulomatosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SWEDEN; T LYMPHOCYTE ACTIVATION; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; FEMALE; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-1; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RATS; TUMOR NECROSIS FACTOR-ALPHA; WEGENER GRANULOMATOSIS;

EID: 0033965453     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Duna GF, Galperin C, Hoffman GS. Wegener's granulomatosis. Rheum Dis Clin N Am 1995;21:949-86.
2. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958;2:265-70.
3. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
4. Guillevin L, Cordier J-F, Lhote F, et al. A prospective, multicenter, randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
5. Barbara JAJ, van Ostade X, Lopez AF. Tumour necrosis factor-alpha: The good, the bad and potentially very effective. Immunol Cell Biol 1996;74:434-43.
6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
7. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43:682-92.
8. Falk RJ, Terrell RS, Chales LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-9.
9. Porges AJ, Redecha PB, Kamberly WT, Csernok E, Gross WL, Kimberly RP. Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via FcgIIa. J Immunol 1994;153:1271-80.
10. Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and Fcγ receptors. J Clin Invest 1997;100:1416-24.
11. Bender JG, McPhail LC, van Epps DE. Exposure of human neutrophils to chemotactic factors potentiates activation of the respiratory burst. J Immunol 1983;130:2316-23.
12. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumour necrosis factor-α. Regulation of N-formylme-thionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988;81:759-65.
13. Ludviksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.
14. Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990;81:311-4.
15. Van der Woud FJ, Lobatto S, Permin H, van der Giessen M, Rasmussen N, Wilk A. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
16. de Bandt M, Ollivier V, Meyer O, et al. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis Rheum 1997;40:2030-8.
17. Brooks CJ, King WJ, Radford DJ, Adu D, McGrath M, Savage COS. IL-1β production by human polymorphonuclear leukocytes stimulated by antineutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996;106:273-9.
18. Giscombe R, Grunewald J, Nityanand S, Lefvert AK. T cell receptor V gene usage in patients with systemic necrotising vasculitis. Clin Exp Immunol 1995;101:213-9.
19. Grunewald J, Halapi E, Wahlström J, et al. T-cell expansion with conserved T-cell receptor β chain motifs in the peripheral blood of HLA-DRB 1*0401 positive patients with necrotizing vasculitis. Blood 1998;92:3737-44.
20. Ten Berge IJM, Wilmink JM, Meyer CJLM, et al. Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis. Am J Nephrol 1985;5:21-9.
21. Rottem M, Cotch MF, Fauci AS, Hoffman GS. Familial vasculitis: report of 2 families. J Rheumatol 1994;21:561-3.
22. Stoney PJ, Davies W, Ho SF, Paterson IC, Griffith IP. Wegener's granulomatosis in two siblings: a family study. J Laryngol Otol 1991;105:123-4.
23. Hay EM, Beaman M, Ralston AJ, Ackrill P, Bernstein RM, Holt PJ. Wegener's granulomatosis occurring in siblings. Br J Rheumatol 1991;30:144-5.
24. Zhang L, Jayne DRW, Zhao MH, Lockwood M, Oliveira DBG. Distribution of MHC class II alleles in primary systemic vasculitis. Kidney Int 1995;47:294-8.
25. Cotch FM, Fauci AS, Hoffman GS. HLA typing in patients with Wegener's granulomatosis [letter]. Ann Intern Med 1995;122:635.
26. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
27. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
28. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, De Groot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol 1995;80:41-5.
29. Nisticò L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, Type 1 diabetes. Hum Mol Genet 1996;5:1075-80.
30. Huang D, Liu L, Norén K, et al. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J Neuroimmunol 1998;88:192-8.
31. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur J Clin Invest 1992;22:396-402.
32. Pociot F, Ronningen KS, Bergholdt R, et al. Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes - evidence for polygenicity in man. Autoimmunity 1994;19:169-78.
33. Huang D, Pirskanen R, Hjelmström P, Lefvert AK. Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998;81:76-81.
34. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNFα) gene detectable by Ncol restriction of PCR product. Hum Mol Genet 1992;1:353.
35. Bouma G, Crusius JBA, Pool MO, et al. Secretion of tumor necrosis factor-a and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
36. Wilson AG, Symons JA, Mcdowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumour necrosis factor transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
37. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
38. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-55.
39. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
40. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
41. Schlesier M, Kaspar T, Gutfleisch J, Wolff-Vorbecl G, Peter H-H. Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995;14:213-9.
42. Ikeda M, Watanabe Y, Kitahara S, Inouye T. Distinctive increases in HLA-DR+ and CD8+57+ lymphocyte subsets in Wegener's granulomatosis. Int Arch Allergy Immunol 1993;102:205-8.
43. Shaw G, Kamen R. A conserved AU sequence from the 3′untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
44. Mascher B, Schmitt W, Csemok E, et al. Polymorphisms in the tumour necrosis factor genes in Wegener's granulomatosis. Exp Clin Immunogenet 1997;14:226-33.
45. Finkel TH, Török TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994;343:1255-8.
46. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995;270:932-3.
47. Miller SD, Vanderlugt CL, Lenschow DJ, et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995;3:739-45.